Resources

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

Aravax announced the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site.

Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. Symbiotic.blue aims to create smarter, multi-targeted therapeutics to tackle complex diseases.

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months.

A Scottish clinical development company is redefining early stage development, taking years off the time it takes for new life improving treatments to become available to patients. BDD Pharma Ltd – based at BioCity Glasgow, one of two Pioneer Group sites in Scotland – has also developed its own, in-house technologies. One of them - OralogiK™ - is a unique patented drug delivery tablet system that enables drugs to be released inside the body at the optimum time, hours after taking the tablets.

The UK’s Minster of State for Science, Research, and Innovation, Lord Patrick Vallance, London & Partners’ CEO, Laura Citron OBE, and Steve Bates OBE, CEO of the UK Bioindustry Association (BIA), are formally launching London Life Sciences Week on the UK stand at the BIO International Convention on Tuesday, 17 June 2025.

In this Q&A blog, BIA spoke to Natasha Gray, Associate & Life Sciences Advisory Service Lead at Warn, a new BIA member.

UK life sciences take centre stage at BIO following a promising Spending Review.

A new residential development in North Cambridge is offering science and technology businesses a ready-made solution to one of the city’s most pressing challenges: housing professional staff within easy reach of major employment hubs.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

BIA has released a new explainer highlighting why the UK is well-positioned to lead in functional genomics, thanks to its unparalleled research capacity and exceptional talent pool.

Steve Bates OBE, CEO of the UK BioIndustry Association, responded to the government's Spending Review.

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.

Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.

PIR International spoke with experienced life science executive, Bob Radie, as part of there BioLeader interview series.